Who are Low-dose cytarabine (LDAC)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Biktarvy, Pifeltro, BICTEGRAVIR SODIUM, Vemlidy, TENOFOVIR ALAFENAMIDE FUMARATE, Lonsurf.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/low-dose-cytarabine-ldac.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Low-dose cytarabine (LDAC) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Low-dose cytarabine (LDAC) (Low-dose cytarabine (LDAC)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside analog; antimetabolite. Area: Oncology.

phase 3 Nucleoside analog; antimetabolite DNA synthesis; cytidine metabolism Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Low-dose cytarabine (LDAC) (Low-dose cytarabine (LDAC)) — Celgene. Low-dose cytarabine is a nucleoside analog that inhibits DNA synthesis by incorporating into DNA and blocking cell division, primarily affecting rapidly dividing hematopoietic cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Low-dose cytarabine (LDAC) TARGET	Low-dose cytarabine (LDAC)	Celgene	phase 3	Nucleoside analog; antimetabolite	DNA synthesis; cytidine metabolism
Biktarvy	BICTEGRAVIR	Gilead Sciences	marketed	Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]		2018-01-01
Pifeltro	DORAVIRINE	Merck & Co.	marketed	Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]		2018-01-01
BICTEGRAVIR SODIUM	BICTEGRAVIR SODIUM		marketed	Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]		2018-01-01
Vemlidy	TENOFOVIR ALAFENAMIDE	Gilead Sciences	marketed	Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]		2015-01-01
TENOFOVIR ALAFENAMIDE FUMARATE	TENOFOVIR ALAFENAMIDE FUMARATE		marketed	Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]		2015-01-01
Lonsurf	TIPIRACIL	Taiho Oncology Inc	marketed	Nucleoside Analog Antiviral [EPC]	Thymidine phosphorylase	2015-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2029-09-22 — Lonsurf · RE46284 · US
2032-08-15 — Biktarvy · 8754065 · US
2032-08-15 — Biktarvy · 9296769 · US
2033-02-15 — Biktarvy · 8754065*PED · US
2033-02-15 — Biktarvy · 9296769*PED · US
2033-12-19 — Biktarvy · 9216996 · US
2033-12-19 — Biktarvy · 9732092 · US
2034-06-17 — Lonsurf · 10457666 · US
2034-06-17 — Lonsurf · 9527833 · US
2034-09-05 — Lonsurf · 9943537 · US
2035-06-19 — Biktarvy · 9708342 · US
2035-06-19 — Biktarvy · 10385067 · US
2036-11-08 — Biktarvy · 10548846 · US
2037-02-03 — Lonsurf · 10960004 · US
2037-02-03 — Lonsurf · 10456399 · US

Sponsor landscape (Nucleoside analog; antimetabolite class)

Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Astellas Pharma Global Development, Inc. · 1 drug in this class
AstraZeneca · 1 drug in this class
Celgene · 1 drug in this class
Centre Hospitalier Universitaire Dijon · 1 drug in this class
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · 1 drug in this class
Eisai Inc. · 1 drug in this class
Gruppo Italiano Malattie EMatologiche dell'Adulto · 1 drug in this class
Jiangsu Simcere Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Low-dose cytarabine (LDAC) — Competitive Intelligence Brief. https://druglandscape.com/ci/low-dose-cytarabine-ldac. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab